Core Viewpoint - ANI Pharmaceuticals is well-positioned to continue its earnings-beat streak in upcoming reports, having surpassed earnings estimates consistently in recent quarters [1][2]. Earnings Performance - ANI Pharmaceuticals has topped earnings estimates by an average of 16.57% over the last two quarters [1]. - In the last reported quarter, ANI achieved earnings of $1.02 per share, exceeding the Zacks Consensus Estimate of $0.93 per share by 9.68% [1]. - For the previous quarter, ANI's actual earnings were $1.21 per share against an expected $0.98 per share, resulting in a surprise of 23.47% [1]. Earnings Estimates and Predictions - Estimates for ANI have been trending higher due to its history of earnings surprises [2]. - The stock has a positive Zacks Earnings ESP of +2.50%, indicating bullish sentiment among analysts regarding its near-term earnings potential [3]. - The combination of a positive Earnings ESP and a Zacks Rank 1 (Strong Buy) suggests a high likelihood of another earnings beat [3]. Importance of Earnings ESP - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [3]. - A positive Earnings ESP enhances the predictive power of potential earnings beats, while a negative value does not necessarily indicate an earnings miss [3][4]. - Utilizing the Earnings ESP Filter can help identify stocks with the best potential for success before earnings reports [4].

Piper Sandler has initiated coverage on ANI Pharmaceuticals ANIP, an integrated specialty pharmaceutical firm that develops and markets branded and generic medicines.The analyst notes that ANI’s business model has significantly transformed, shifting from a primary emphasis on generics to a new focus on integrating high-margin brand assets aimed at rare diseases. Cortrophin Gel (adrenocorticotropic hormone (ACTH)), the company’s lead asset, has been the centerpiece of that evolution.Cortrophin gel sales more ...

Biotech Forum Discussion - The Biotech Forum has been focused on lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months [1] - The forum offers real-time trading ideas and insights from seasoned biotech investors [1] ANI Pharmaceuticals Spotlight - ANI Pharmaceuticals Inc (NASDAQ: ANIP) is highlighted as a small but growing biopharma company [1] - The equity is considered one of the few reasonable growth at a reasonable price (GARP) stocks in the biotech sector [1] The Biotech Forum Services - The Biotech Forum provides a model portfolio featuring 12-20 high upside biotech stocks [1] - The forum offers live chat for discussing trade ideas, weekly research, and option trades [1] - Market commentary and portfolio updates are provided every weekend [1]

ANI Pharmaceuticals (ANIP) closed the last trading session at $56.79, gaining 2.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $81.20 indicates a 43% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $13.70. While the lowest estimate of $60 indicates a 5.7% increase from the current price level, the most optimistic analyst e ...

Core Insights - The Zacks Rank system emphasizes earnings estimates and revisions to identify winning stocks, with a focus on value investing as a popular strategy in various market conditions [1] - Zacks has introduced the Style Scores system to highlight stocks with specific characteristics, particularly those with high grades in the "Value" category, which are considered strong value stocks when combined with a high Zacks Rank [1] Company Summary: ANI Pharmaceuticals (ANIP) - ANI Pharmaceuticals currently holds a Zacks Rank of 2 (Buy) and has received a Value grade of A, indicating strong potential for value investors [2] - The company's price-to-book (P/B) ratio is 2.64, which is favorable compared to the industry average of 3.88. Over the past 12 months, ANIP's P/B ratio has fluctuated between 2.31 and 3.30, with a median of 2.83 [2] - ANI Pharmaceuticals has a price-to-cash flow (P/CF) ratio of 12.75, which is attractive relative to the industry average of 15.70. The P/CF ratio has ranged from 11.93 to 19.50 over the past 52 weeks, with a median of 13.70 [2] - These metrics suggest that ANI Pharmaceuticals is likely undervalued at present, especially when considering its strong earnings outlook, making it an impressive value stock [3]

PRINCETON, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Ketoconazole Shampoo, 2%. ANI’s Ketoconazole Shampoo, 2% is the generic version of the reference listed drug (RLD) Nizoral®. "We are proud to announce the FDA approval and commercialization of Ketoconazole Shampoo, 2%, another limite ...

PRINCETON, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) --  ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, 6.25 mg/15 mg per 5 mL. "The launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution just prior to the onset of cough and cold season is especially timely. With our 14th new product launch this year, we continue to drive strong growth in our Generics business,” ...

PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly announced that they have scheduled the closing of their transaction pursuant to the companies’ previously announced Merger Agreement for before the market opens on Monday, September 16, 2024. About ANI Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...

PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the closing of its offering of $316,250,000 aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In response to investor demand, ANI upsized the initial offering of $250,000,000 aggregate principal amount ...